Injection, Infliximab, Excludes Biosimilar, 10 Mg in Tennessee

Tennessee Pricing in Context

In Tennessee, CPT code J1745 (Injection, Infliximab, Excludes Biosimilar, 10 Mg) carries an average Medicare payment of $25.53 - 1% below the national benchmark of $25.84. 190 providers across the state submitted claims for this procedure in 2023, performing 247.9K total services. Payment ranges by individual claim are not published in this CMS extract; the state average above is the figure to compare against the national benchmark.

The average billed charge in Tennessee is $134.33, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount, the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Tennessee sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Tennessee lands near $69.31, with self-pay cash prices typically around $61.12. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.